Biotech Stocks Rally on Trial Progress, Funding, and Milestones

Biotech stocks rallied after hours driven by clinical trial updates, funding announcements, and upcoming milestones. Prime Medicine rose 8.14% to $5.05, Meihua International Medical Technologies gained 7.55% to $0.4444, Elutia surged 10.17% to $1.30, and Aligos Therapeutics increased 2.79% to $9.20. The stocks were boosted by recent clinical data and upcoming product showcases, including Prime Medicine's CGD program and Elutia's biologic envelopes.

Biotech stocks experienced a significant rally after hours on September 12, 2025, driven by recent clinical trial updates, funding announcements, and upcoming milestones. Prime Medicine (NASDAQ:PRIM) rose 8.14% to $5.05, Meihua International Medical Technologies (NASDAQ:MEIH) gained 7.55% to $0.4444, Elutia (NASDAQ:ELUT) surged 10.17% to $1.30, and Aligos Therapeutics (NASDAQ:ALIG) increased 2.79% to $9.20. The stocks were boosted by recent clinical data and upcoming product showcases, including Prime Medicine's CGD program and Elutia's biologic envelopes.

Ascendis Pharma (NASDAQ:ASND) is one of the top biotech picks by BofA Global Research, with a $230 price objective. The company is approaching a critical milestone with its TransCon CNP treatment for achondroplasia, which has a PDUFA action date of November 30th. Analysts assign a 90% likelihood of success to this program and project peak risk-adjusted sales of $1.1 billion. Additionally, Ascendis plans to launch Skytrofa for adult growth hormone disease in the fourth quarter following its July approval Top 3 Biotech Stocks to Watch According to BofA Global Research^[1].

Kymera Therapeutics (NASDAQ:KYMR) is another top pick with a $54 price objective. The company is on track to report Phase 1b BroADen data for its STAT6 degrader (KT-621) in moderate-to-severe atopic dermatitis during the fourth quarter of 2025. Management aims to demonstrate robust STAT6 degradation in blood and skin lesions, along with suppression of Th2 biomarkers. The trial will also assess exploratory clinical endpoints including EASI-75 and pruritus NRS at days 7, 14, 21, and 28 Top 3 Biotech Stocks to Watch According to BofA Global Research^[1].

Merus NV (NASDAQ:MRUS) has a $92 price objective and is expanding the development of its lead asset, petosemtamab (an EGFR x LGR5 bispecific antibody), beyond head and neck squamous cell carcinoma. Merus plans to provide an initial update on its Phase 2 study in metastatic colorectal cancer in the second half of 2025, likely at a medical meeting. Management expects to benchmark objective response rates against current EGFR-based therapies Top 3 Biotech Stocks to Watch According to BofA Global Research^[1].

Elutia, which saw a 10.17% increase, received clearance for Elupro in June 2024 and began a full commercial launch at the start of 2025. The device has an extracellular matrix to support wound healing and potentially facilitate re-operative procedures by reducing scar formation and fibrosis. Elupro gradually releases the antibiotics rifampin and minocycline into the surrounding tissue to provide antimicrobial protection after the procedure Boston Scientific inks $88M Elutia deal to challenge Medtronic^[2].

Boston Scientific has agreed to buy Elutia’s two bioenvelope products for $88 million, the companies said Tuesday. The agreement will give Boston Scientific control of Elupro and Cangaroo, devices designed to promote wound healing to prevent complications after pacemaker or defibrillator implantation. Elupro and Cangaroo compete with Medtronic’s TYRX. BTIG analysts said in a note to investors that they believe “the Elupro bioenvelope may offer clinical and handling advantages over TYRX” Boston Scientific inks $88M Elutia deal to challenge Medtronic^[2].

The rally in biotech stocks underscores the importance of clinical trial updates and upcoming milestones in driving shareholder value. Investors should closely monitor these developments as they continue to shape the performance of these companies.